Skip to main content
. Author manuscript; available in PMC: 2024 Aug 1.
Published in final edited form as: Arthritis Rheumatol. 2021 May 2;73(6):931–942. doi: 10.1002/art.41622

Table 1.

Prediction power of the clinical- pharmacogenetic and metagenomic- based models for predicting response to MTX in patients with new- onset RA in our validation cohort*

Clinical-pharmacogenetic model Metagenomic-based model

Patients classified as MTX nonresponders or MTX responders 48.9 100
True- negative rate 69 83.3
True- positive rate 0 78
*

Values are the percent. MTX = methotrexate; RA = rheumatoid arthritis.